Although tyrosine kinase inhibitor (TKI) therapy achieves a higher objective response rate and longer progression free survival in cancers with epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK)-rearrangement, relapse is the rule after 10-14 months due to drug resistance [1-5]. Here, EGFR is linked to cancer.